Ribavirin - PENDOPHARM

Drug Profile

Ribavirin - PENDOPHARM

Alternative Names: IBAVYR; RBV - PENDOPHARM

Latest Information Update: 18 Jul 2014

Price : $50

At a glance

  • Originator PENDOPHARM
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Nucleic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Jul 2014 Launched for Hepatitis C in Canada (PO)
  • 15 Jul 2014 Registered for Hepatitis C in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top